Prohibitin is involved in the activated internalization and degradation of protease-activated receptor 1

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1843, Issue 7, 2014, Pages 1393-1401

  Wang, Yan Jie ^a   Guo, Xiao Long ^a,b   Li, Sheng An ^a   Zhao, Yu Qi ^a   Liu, Zi Chao ^c   Lee, Wen Hui ^a   Xiang, Yang ^a   Zhang, Yun ^a  

^a KUNMING INSTITUTE OF ZOOLOGY   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c KUNMING UNIVERSITY   (China)

Author keywords

Activated internalization; Erk1 2 signaling degradation; PAR1; Prohibitin

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROHIBITIN; PROTEINASE ACTIVATED RECEPTOR 1; RNA; MAPK1 PROTEIN, HUMAN; PEPTIDE; REPRESSOR PROTEIN; SMALL INTERFERING RNA;

ARTICLE; CANCER CELL; CELL SURFACE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INTERNALIZATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; THROMBOCYTE AGGREGATION; THROMBOCYTE MEMBRANE; ANTAGONISTS AND INHIBITORS; ANTIBODY SPECIFICITY; CELL MOTION; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PROTEIN TRANSPORT; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL;

CELL LINE, TUMOR; CELL MOVEMENT; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICROSCOPY, CONFOCAL; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; ORGAN SPECIFICITY; PEPTIDES; PROTEIN TRANSPORT; PROTEOLYSIS; RECEPTOR, PAR-1; REPRESSOR PROTEINS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 84899581252     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2014.04.005     Document Type: Article

References (33)

1. Da Cruz S., Parone P.A., Gonzalo P., Bienvenut W.V., Tondera D., Jourdain A., Quadroni M., Martinou J.C. SLP-2 interacts with prohibitins in the mitochondrial inner membrane and contributes to their stability. Biochim. Biophys. Acta 2008, 1783:904-911.
2. Rizwani W., Alexandrow M., Chellappan S. Prohibitin physically interacts with MCM proteins and inhibits mammalian DNA replication. Cell Cycle 2009, 8:1621-1629.
3. Sharma A., Qadri A. Vi polysaccharide of Salmonella typhi targets the prohibitin family of molecules in intestinal epithelial cells and suppresses early inflammatory responses. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:17492-17497.
4. Kuadkitkan A., Wikan N., Fongsaran C., Smith D.R. Identification and characterization of prohibitin as a receptor protein mediating DENV-2 entry into insect cells. Virology 2010, 406:149-161.
5. Zhang Y., Wang Y., Xiang Y., Lee W. Prohibitins are involved in protease-activated receptor 1-mediated platelet aggregation. J. Thromb. Haemost. 2012, 10:411-418.
6. Rajalingam K., Wunder C., Brinkmann V., Churin Y., Hekman M., Sievers C., Rapp U.R., Rudel T. Prohibitin is required for Ras-induced Raf-MEK-ERK activation and epithelial cell migration. Nat. Cell Biol. 2005, 7:837-843.
7. Theiss A.L., Sitaraman S.V. The role and therapeutic potential of prohibitin in disease. Biochim. Biophys. Acta 2011, 1813:1137-1143.
8. Hamrita B., Chahed K., Kabbage M., Guillier C.L., Trimeche M., Chaieb A., Chouchane L. Identification of tumor antigens that elicit a humoral immune response in breast cancer patients' sera by serological proteome analysis (SERPA). Clin. Chim. Acta 2008, 393:95-102.
9. Ossovskaya V.S., Bunnett N.W. Protease-activated receptors: contribution to physiology and disease. Physiol. Rev. 2004, 84:579-621.
10. Ramachandran R., Noorbakhsh F., Defea K., Hollenberg M.D. Targeting proteinase-activated receptors: therapeutic potential and challenges. Nat. Rev. Drug Discov. 2012, 11:69-86.
11. Tsopanoglou N.E., Maragoudakis M.E. Inhibition of angiogenesis by small-molecule antagonists of protease-activated receptor-1. Semin. Thromb. Hemost. 2007, 33:680-687.
12. Coughlin S.R. Thrombin signalling and protease-activated receptors. Nature 2000, 407:258-264.
13. Hollenberg M.D., Saifeddine M., al-Ani B., Kawabata A. Proteinase-activated receptors: structural requirements for activity, receptor cross-reactivity, and receptor selectivity of receptor-activating peptides. Can. J. Physiol. Pharmacol. 1997, 75:832-841.
14. Soh U.J., Dores M.R., Chen B., Trejo J. Signal transduction by protease-activated receptors. Br. J. Pharmacol. 2010, 160:191-203.
15. Paing M.M., Johnston C.A., Siderovski D.P., Trejo J. Clathrin adaptor AP2 regulates thrombin receptor constitutive internalization and endothelial cell resensitization. Mol. Cell. Biol. 2006, 26:3231-3242.
16. Chen B., Dores M.R., Grimsey N., Canto I., Barker B.L., Trejo J. Adaptor protein complex-2 (AP-2) and epsin-1 mediate protease-activated receptor-1 internalization via phosphorylation- and ubiquitination-dependent sorting signals. J. Biol. Chem. 2011, 286:40760-40770.
17. Dores M.R., Chen B., Lin H., Soh U.J., Paing M.M., Montagne W.A., Meerloo T., Trejo J. ALIX binds a YPX(3)L motif of the GPCR PAR1 and mediates ubiquitin-independent ESCRT-III/MVB sorting. J. Cell Biol. 2012, 197:407-419.
18. Wang Y., Zhou Y., Szabo K., Haft C.R., Trejo J. Down-regulation of protease-activated receptor-1 is regulated by sorting nexin 1. Mol. Biol. Cell 2002, 13:1965-1976.
19. Horvat R., Palade G.E. The functional thrombin receptor is associated with the plasmalemma and a large endosomal network in cultured human umbilical vein endothelial cells. J. Cell Sci. 1995, 108(Pt 3):1155-1164.
20. Bahou W.F. Protease-activated receptors. Curr. Top. Dev. Biol. 2003, 54:343-369.
21. Peng X., Mehta R., Wang S., Chellappan S., Mehta R.G. Prohibitin is a novel target gene of vitamin D involved in its antiproliferative action in breast cancer cells. Cancer Res. 2006, 66:7361-7369.
22. Booden M.A., Eckert L.B., Der C.J., Trejo J. Persistent signaling by dysregulated thrombin receptor trafficking promotes breast carcinoma cell invasion. Mol. Cell. Biol. 2004, 24:1990-1999.
23. Li S.A., Xiang Y., Wang Y.J., Liu J., Lee W.H., Zhang Y. Naturally occurring antimicrobial peptide OH-CATH30 selectively regulates the innate immune response to protect against sepsis. J. Med. Chem. 2013, 56:9136-9145.
24. Kim D.K., Kim H.S., Kim A.R., Jang G.H., Kim H.W., Park Y.H., Kim B., Park Y.M., Beaven M.A., Kim Y.M., Choi W.S. The scaffold protein prohibitin is required for antigen-stimulated signaling in mast cells. Sci. Signal. 2013, 6:ra80.
25. Christoforidis S., McBride H.M., Burgoyne R.D., Zerial M. The Rab5 effector EEA1 is a core component of endosome docking. Nature 1999, 397:621-625.
26. Mishra S., Murphy L.C., Murphy L.J. The prohibitins: emerging roles in diverse functions. J. Cell. Mol. Med. 2006, 10:353-363.
27. Browman D.T., Hoegg M.B., Robbins S.M. The SPFH domain-containing proteins: more than lipid raft markers. Trends Cell Biol. 2007, 17:394-402.
28. Glebov O.O., Bright N.A., Nichols B.J. Flotillin-1 defines a clathrin-independent endocytic pathway in mammalian cells. Nat. Cell Biol. 2006, 8:46-54.
29. Manjeshwar S., Lerner M.R., Zang X.P., Branam D.E., Pento J.T., Lane M.M., Lightfoot S.A., Brackett D.J., Jupe E.R. Expression of prohibitin 3' untranslated region suppressor RNA alters morphology and inhibits motility of breast cancer cells. J. Mol. Histol. 2004, 35:639-646.
30. Henrikson K.P., Salazar S.L., Fenton J.W., Pentecost B.T. Role of thrombin receptor in breast cancer invasiveness. Br. J. Cancer 1999, 79:401-406.
31. Gourlaouen M., Welti J.C., Vasudev N.S., Reynolds A.R. Essential role for endocytosis in the growth factor-stimulated activation of ERK1/2 in endothelial cells. J. Biol. Chem. 2013, 288:7467-7480.
32. Hitchcock I.S., Chen M.M., King J.R., Kaushansky K. YRRL motifs in the cytoplasmic domain of the thrombopoietin receptor regulate receptor internalization and degradation. Blood 2008, 112:2222-2231.
33. Audet N., Paquin-Gobeil M., Landry-Paquet O., Schiller P.W., Pineyro G. Internalization and Src activity regulate the time course of ERK activation by delta opioid receptor ligands. J. Biol. Chem. 2005, 280:7808-7816.